Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4055 | Training load Wiki | 1.00 |
| drug2928 | Placebo - Starch Powder Soft gels Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D014777 | Virus Diseases NIH | 0.11 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a double blind randomized placebo controlled study will be conducted on 124 subjects, 50 years and older with mild or asymptomatic COVID-19. If symptomatic, symptoms are mild (cough, weakness, sore throat, low grade fever 38.50С, respiratory rate should not be more than 22 / min, resting SpO2 >95%, normal highly sensitive C-reactive protein (HS-CRP) (<10mg/L). There are no signs of dehydration, sepsis or shortness of breath. The study will be conducted at two centers. There will be a screening visit at Day -4 followed by three visits at the center at Days 1, 7 and 15 and a follow-up visit on Day 28. All participants will be randomized to receive either ViraCide (investigational product) or matching placebo. All subjects will receive SOC therapy. Note: If subject is discharged before Day 15 PI's discretion as per patients health condition, then assessments scheduled for Day 15 will be carried out on the discharge day (as far as possible and those not performed will be noted on appropriate CRF page) and Day 15 visit will be done telephonically.
Description: Time to Clinical Improvement (TTCI) using NEWS Score23 [Time Frame:First treatment date up to discharge day (PI's discretion as per patient's health condition)] The median time in days from the start of treatment with the study drug / placebo to the persistent achievement of all of the following criteria: i. Stopping a fever (which is defined as a decrease in axillary temperature below 37 ° C without the use of antipyretic drugs); ii. Respiratory rate <22 /min; iii. Oxygen saturation (SPO2) > 95% when breathing in atmospheric air. Measured using pulse oximetry iv. Systolic blood pressure ≤200mmHg v. Pulse rate 51-90beats/minute vi. Is conscious and alert
Measure: NEWS Score Time: First treatment date up to day 15Description: TTIC using 7-point ordinal scale3 [Time Frame: First treatment date up to discharge day (PI's discretion as per patients health condition)]
Measure: 7-point ordinal scale Time: First treatment date up to day 15Description: Rate of progression to severe/critical COVID-19 disease based on NEWS score
Measure: Rate of progression on NEWS score Time: First treatment date up to 15 daysDescription: Rate of progression to severe/critical COVID-19 disease based on 7-point
Measure: Rate of progression on 7 point ordinal score Time: First treatment date up to 28daysDescription: Time to COVID-19 nucleic acid testing negativity in oropharyngeal/nasal swab)
Measure: Time to COVID-19 nucleic acid testing Time: Time Frame: First treatment date up to 28daysDescription: Incidence of ICU admissions
Measure: ICU admissions Time: Time Frame: 28daysDescription: Subject survival rate
Measure: survival rate Time: Time Frame: 28 daysDescription: Incidence of mechanical ventilation
Measure: mechanical ventilation Time: Time Frame: First treatment date up to 28 days]Description: Time to COVID-19 nucleic acid testing negativity in oropharyngeal/nasal swab)
Measure: Time to COVID-19 nucleic acid testing Time: Time Frame: Days 1, 7, 15Description: Change in clinical or laboratory assessment of comorbid condition
Measure: Assessmentofcomorbidcondition Time: Time Frame: First treatment date up to 28days]Description: Percent of participants with worsening comorbid condition
Measure: worsening comorbid condition Time: Time Frame: First treatment date up to 28days]Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports